Frontlight ResearchEarly access
Active, not recruitingNo phase
Esophageal String Test in Eosinophilic Esophagitis
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Aurora, Chicago, Indianapolis, and Peoria, United StatesSee the 6 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 440 people, planned
- Started
- Jan 2009
- Expected to end
- Jan 2027
- Type of study
- Observational, 3 groups
- Record updated
- 15 May 2026
Who can take part
- Age
- 7 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients undergoing esophagogastroduodenoscopy (EGD) at Children's Hospital Colorado, or
- Patients from a participating site in whom an inflammatory GI disease is suspected
- Patients with symptoms of:; abdominal pain,; vomiting,; growth delay, or; malabsorption for which an etiology has not been determined
- Patients with chronic eosinophilic esophagitis (EoE) in whom symptoms suggest ongoing inflammation
Who cannot take part
- Patients suffering from bleeding diathesis, or any other comorbid condition which their doctor feels may put them at additional risk
- Patients with a family history of connective tissue disease
- Patients with a history of:; esophageal stricture, or; surgery such as fundoplication, or; allergy to gelatin, or; inability to swallow pills
- Patients undergoing a therapeutic endoscopy (such as dilatation, sclerotherapy, variceal banding)
Where in United States
- Children's Hospital ColoradoAurora, United States
- University of Colorado HospitalAurora, United States
- Lurie Children's HospitalChicago, United States
- Northwestern UniversityChicago, United States
- Indiana UniversityIndianapolis, United States
- OSF St Francis Medical CenterPeoria, United States
About the trial
What the trial wants to find out
The overall goal of this study is to develop a novel minimally invasive device, the Esophageal String Test (EST) to monitor esophageal inflammation during treatment of the rare disease Eosinophilic Esophagitis (EoE) in a safe and efficacious manner.
Read full original descriptionShow less
This study is broken down into 2 specific aims:
Specific Aim 1: Identify the EoE Biomarker Panel (EBP) that will improve the sensitivity and specificity of the EST for documenting esophageal inflammation in a 1-hour time point.
Specific Aim 2: Validate the ability of the EST EBP to monitor therapeutic efficacy in a 1-hour sampling time.
Funding Source - FDA OOPD
The 3 groups in the trial
- EoE active disease
Inflammation as defined by \>15 eos / HPF
- EoE remission
No inflammation in EoE patients after treatment
- normal control
No inflammation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 2 Study of Esophageal String Test in Diagnosing Eosinophilic Esophagitis
- Record updated
- 15 May 2026